Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotaverine to prevent postoperative pancreatic fistula after distal pancreatectomy
ChiCTR2600124675Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of drotaverine in pancreatic fistula (POPF), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Drain fluid amylase (DFA). Planned start May 2026; status: not yet recruiting.
02
Drugs
drotaverine
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on ChiCTR2600124675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124675.